Atom Bioscience to Update Clinical Development of New Drug to Treat Gout at BIO International Convention, June 13 – 16, 2022, San Diego, CA

JIANGSU, China–()–Atom Bioscience, a clinical stage biotechnology company developing new treatments for inflammatory and metabolic diseases, announced today it will update its clinical development of ABP-671, the company’s new oral drug for chronic gout, during a presentation at the BIO International Convention on June 13 – 16, 2022, at the San Diego Convention Center, San Diego, CA. The convention is the world’s largest gathering of biotech executives, scientists and academic researchers.

Roy J. Wu, Senior Vice President of Business Development, will make the Atom Bioscience company presentation Monday, June 13, 12:45 pm – 1 pm (PDT) in Company Presentation Theater 1 on the Exhibit Floor of the San Diego Convention Center. In addition to updating clinical development of ABP-671, the company’s lead drug candidate, Mr. Wu will review Atom’s pipeline of other best-in-class small molecule therapeutics.

Gout is one of the most common types of inflammatory arthritis affecting 55 million people worldwide and more than 9.3 million in the US. It is caused by a long-term condition known as hyperuricemia, the excessive build-up of uric acid in the blood (> 7 mg/dL).

Atom’s Phase 2a randomized double-blind, placebo-controlled clinical trial in Australia of ABP-671, a second generation oral URTA1 inhibitor, achieved its primary endpoint of reducing uric acid to less than 6 mg/dL. Significantly, no safety concerns were reported. Based on these findings, the company expects to launch global pivotal Phase 3 studies shortly.

To learn more about chronic gout, see video from expert Dr. Lawrence Edwards, Vice Chairman and Professor, Department of Medicine, University of Florida. Dr. Edwards is an Atom Bioscience adviser.

About Atom Bioscience

Atom Bioscience (Jiangsu Atom Bioscience and Pharmaceutical Co. Ltd.) is a fast-growing innovative drug company, focused on development of best in class small molecule therapeutics for treatment of inflammatory and metabolic diseases. The company’s lead product, ABP-671, is in clinical development for treatment of chronic gout. For more information please visit:

Source link

The content is by Business Wire. Headlines of Today Media is not responsible for the content provided or any links related to this content. Headlines of Today Media is not responsible for the correctness, topicality or the quality of the content.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy